摘要
临床强直性脊柱炎(AS)治疗以肿瘤坏死因子(TNF)-α抑制剂为主,依那西普作为重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白广泛应用于临床并取得较好疗效。本文从药物经济学角度对依那西普治疗AS的临床获益及疾病负担等进行系统综述。
The main clinical treatment for ankylosing spondylitis （AS） is using tumor necrosis factor （TNF）-α inhibitors, etanercept, as a recombinant dimeric fusion protein that competitively antagonises the action of TNF-α upon its receptor has been widely used in clinical practice and achieved great effect. In this review, the authors have reviewed systemically from pharmacoeconomics point of viewing etanercept for AS, including its clinical benefit and economic burden and so on.
出处
《世界临床药物》
CAS
2014年第3期189-192,I0001,共5页
World Clinical Drug
基金
国家自然科学基金项目(81072469
30671946)
上海市自然科学基金(09ZRl417600)
